Zhejiang Hisun Pharmaceutical Co Ltd (600267) - Net Assets
Based on the latest financial reports, Zhejiang Hisun Pharmaceutical Co Ltd (600267) has net assets worth CN¥8.76 Billion CNY (≈ $1.28 Billion USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥15.32 Billion ≈ $2.24 Billion USD) and total liabilities (CN¥6.56 Billion ≈ $960.28 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Zhejiang Hisun Pharmaceutical Co Ltd asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥8.76 Billion |
| % of Total Assets | 57.16% |
| Annual Growth Rate | 15.29% |
| 5-Year Change | 3.9% |
| 10-Year Change | 5.07% |
| Growth Volatility | 40.08 |
Zhejiang Hisun Pharmaceutical Co Ltd - Net Assets Trend (1997–2024)
This chart illustrates how Zhejiang Hisun Pharmaceutical Co Ltd's net assets have evolved over time, based on quarterly financial data. Also explore how large is Zhejiang Hisun Pharmaceutical Co Ltd's balance sheet for the complete picture of this company's asset base.
Annual Net Assets for Zhejiang Hisun Pharmaceutical Co Ltd (1997–2024)
The table below shows the annual net assets of Zhejiang Hisun Pharmaceutical Co Ltd from 1997 to 2024. For live valuation and market cap data, see Zhejiang Hisun Pharmaceutical Co Ltd market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥8.58 Billion ≈ $1.26 Billion |
+2.75% |
| 2023-12-31 | CN¥8.35 Billion ≈ $1.22 Billion |
+0.23% |
| 2022-12-31 | CN¥8.33 Billion ≈ $1.22 Billion |
+13.41% |
| 2021-12-31 | CN¥7.35 Billion ≈ $1.07 Billion |
-11.03% |
| 2020-12-31 | CN¥8.26 Billion ≈ $1.21 Billion |
+7.47% |
| 2019-12-31 | CN¥7.68 Billion ≈ $1.12 Billion |
+4.12% |
| 2018-12-31 | CN¥7.38 Billion ≈ $1.08 Billion |
-6.31% |
| 2017-12-31 | CN¥7.88 Billion ≈ $1.15 Billion |
-2.04% |
| 2016-12-31 | CN¥8.04 Billion ≈ $1.18 Billion |
-1.54% |
| 2015-12-31 | CN¥8.17 Billion ≈ $1.19 Billion |
-1.20% |
| 2014-12-31 | CN¥8.26 Billion ≈ $1.21 Billion |
+38.71% |
| 2013-12-31 | CN¥5.96 Billion ≈ $871.87 Million |
+14.63% |
| 2012-12-31 | CN¥5.20 Billion ≈ $760.59 Million |
+13.15% |
| 2011-12-31 | CN¥4.59 Billion ≈ $672.18 Million |
+67.39% |
| 2010-12-31 | CN¥2.74 Billion ≈ $401.57 Million |
+12.90% |
| 2009-12-31 | CN¥2.43 Billion ≈ $355.67 Million |
+56.89% |
| 2008-12-31 | CN¥1.55 Billion ≈ $226.70 Million |
+12.51% |
| 2007-12-31 | CN¥1.38 Billion ≈ $201.50 Million |
+8.38% |
| 2006-12-31 | CN¥1.27 Billion ≈ $185.92 Million |
+3.47% |
| 2005-12-31 | CN¥1.23 Billion ≈ $179.69 Million |
+2.16% |
| 2004-12-31 | CN¥1.20 Billion ≈ $175.90 Million |
+19.99% |
| 2003-12-31 | CN¥1.00 Billion ≈ $146.59 Million |
+21.45% |
| 2002-12-31 | CN¥824.83 Million ≈ $120.70 Million |
+5.18% |
| 2001-12-31 | CN¥784.18 Million ≈ $114.75 Million |
+3.47% |
| 2000-12-31 | CN¥757.90 Million ≈ $110.90 Million |
+203.31% |
| 1999-12-31 | CN¥249.88 Million ≈ $36.56 Million |
+27.16% |
| 1998-12-31 | CN¥196.50 Million ≈ $28.75 Million |
+6.66% |
| 1997-12-31 | CN¥184.23 Million ≈ $26.96 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Zhejiang Hisun Pharmaceutical Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 253810069600.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥2.54 Billion | 30.43% |
| Common Stock | CN¥1.20 Billion | 14.37% |
| Other Components | CN¥4.60 Billion | 55.20% |
| Total Equity | CN¥8.34 Billion | 100.00% |
Zhejiang Hisun Pharmaceutical Co Ltd Competitors by Market Cap
The table below lists competitors of Zhejiang Hisun Pharmaceutical Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Veeco Instruments Inc
NASDAQ:VECO
|
$2.03 Billion |
|
Shenzhen Rongda Photosensitive & Technology Co Ltd
SHE:300576
|
$2.03 Billion |
|
Westone Information Industry Inc
SHE:002268
|
$2.03 Billion |
|
Schiehallion Fund Ltd
LSE:MNTN
|
$2.03 Billion |
|
AMP Limited
F:AMP
|
$2.03 Billion |
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
|
$2.03 Billion |
|
Ocular Therapeutix Inc
NASDAQ:OCUL
|
$2.02 Billion |
|
Triumph Group Inc
NYSE:TGI
|
$2.02 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Zhejiang Hisun Pharmaceutical Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 8,101,974,562 to 8,341,353,163, a change of 239,378,601 (3.0%).
- Net income of 601,182,833 contributed positively to equity growth.
- Dividend payments of 148,471,079 reduced retained earnings.
- Share repurchases of 172,776,576 reduced equity.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥601.18 Million | +7.21% |
| Dividends Paid | CN¥148.47 Million | -1.78% |
| Share Repurchases | CN¥172.78 Million | -2.07% |
| Other Changes | CN¥-40.56 Million | -0.49% |
| Total Change | CN¥- | 2.95% |
Book Value vs Market Value Analysis
This analysis compares Zhejiang Hisun Pharmaceutical Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.60x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 45.40x to 1.60x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1997-12-31 | CN¥0.25 | CN¥11.55 | x |
| 1998-12-31 | CN¥0.27 | CN¥11.55 | x |
| 1999-12-31 | CN¥0.33 | CN¥11.55 | x |
| 2000-12-31 | CN¥1.04 | CN¥11.55 | x |
| 2001-12-31 | CN¥1.07 | CN¥11.55 | x |
| 2002-12-31 | CN¥1.12 | CN¥11.55 | x |
| 2003-12-31 | CN¥1.36 | CN¥11.55 | x |
| 2004-12-31 | CN¥1.64 | CN¥11.55 | x |
| 2005-12-31 | CN¥1.69 | CN¥11.55 | x |
| 2006-12-31 | CN¥1.74 | CN¥11.55 | x |
| 2007-12-31 | CN¥1.90 | CN¥11.55 | x |
| 2008-12-31 | CN¥2.11 | CN¥11.55 | x |
| 2009-12-31 | CN¥3.30 | CN¥11.55 | x |
| 2010-12-31 | CN¥3.50 | CN¥11.55 | x |
| 2011-12-31 | CN¥5.45 | CN¥11.55 | x |
| 2012-12-31 | CN¥5.60 | CN¥11.55 | x |
| 2013-12-31 | CN¥5.83 | CN¥11.55 | x |
| 2014-12-31 | CN¥7.98 | CN¥11.55 | x |
| 2015-12-31 | CN¥5.10 | CN¥11.55 | x |
| 2016-12-31 | CN¥7.15 | CN¥11.55 | x |
| 2017-12-31 | CN¥7.03 | CN¥11.55 | x |
| 2018-12-31 | CN¥6.40 | CN¥11.55 | x |
| 2019-12-31 | CN¥6.50 | CN¥11.55 | x |
| 2020-12-31 | CN¥6.92 | CN¥11.55 | x |
| 2021-12-31 | CN¥6.43 | CN¥11.55 | x |
| 2022-12-31 | CN¥7.01 | CN¥11.55 | x |
| 2023-12-31 | CN¥6.96 | CN¥11.55 | x |
| 2024-12-31 | CN¥7.21 | CN¥11.55 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Zhejiang Hisun Pharmaceutical Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 7.21%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 6.14%
- • Asset Turnover: 0.61x
- • Equity Multiplier: 1.91x
- Recent ROE (7.21%) is below the historical average (8.56%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1997 | 28.82% | 19.50% | 0.76x | 1.94x | CN¥34.32 Million |
| 1998 | 24.32% | 16.68% | 0.59x | 2.49x | CN¥27.85 Million |
| 1999 | 21.06% | 13.82% | 0.53x | 2.86x | CN¥25.98 Million |
| 2000 | 6.86% | 9.85% | 0.43x | 1.62x | CN¥-23.37 Million |
| 2001 | 6.35% | 8.43% | 0.44x | 1.70x | CN¥-27.94 Million |
| 2002 | 6.24% | 6.57% | 0.48x | 1.96x | CN¥-30.15 Million |
| 2003 | 17.42% | 10.96% | 0.83x | 1.92x | CN¥72.39 Million |
| 2004 | 18.50% | 12.21% | 0.82x | 1.86x | CN¥99.81 Million |
| 2005 | 9.58% | 6.08% | 0.73x | 2.15x | CN¥-5.11 Million |
| 2006 | 6.60% | 3.57% | 0.82x | 2.25x | CN¥-42.44 Million |
| 2007 | 10.25% | 4.92% | 0.95x | 2.19x | CN¥3.37 Million |
| 2008 | 12.91% | 6.14% | 0.77x | 2.72x | CN¥43.98 Million |
| 2009 | 11.39% | 6.80% | 0.77x | 2.17x | CN¥33.18 Million |
| 2010 | 13.56% | 8.05% | 0.77x | 2.19x | CN¥95.95 Million |
| 2011 | 11.20% | 9.77% | 0.63x | 1.83x | CN¥54.04 Million |
| 2012 | 6.43% | 5.19% | 0.55x | 2.26x | CN¥-167.31 Million |
| 2013 | 6.18% | 3.51% | 0.62x | 2.86x | CN¥-186.82 Million |
| 2014 | 4.38% | 3.05% | 0.58x | 2.46x | CN¥-394.50 Million |
| 2015 | 0.20% | 0.15% | 0.46x | 2.77x | CN¥-678.39 Million |
| 2016 | -1.40% | -0.97% | 0.47x | 3.07x | CN¥-769.94 Million |
| 2017 | 0.20% | 0.13% | 0.49x | 3.22x | CN¥-658.69 Million |
| 2018 | -7.96% | -4.83% | 0.47x | 3.53x | CN¥-1.11 Billion |
| 2019 | 1.48% | 0.84% | 0.52x | 3.42x | CN¥-534.35 Million |
| 2020 | 6.25% | 3.67% | 0.54x | 3.12x | CN¥-250.67 Million |
| 2021 | 6.67% | 4.01% | 0.63x | 2.65x | CN¥-243.44 Million |
| 2022 | 6.05% | 4.06% | 0.64x | 2.32x | CN¥-319.05 Million |
| 2023 | -1.15% | -0.90% | 0.59x | 2.17x | CN¥-903.37 Million |
| 2024 | 7.21% | 6.14% | 0.61x | 1.91x | CN¥-232.95 Million |
Industry Comparison
This section compares Zhejiang Hisun Pharmaceutical Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $3,517,854,642
- Average return on equity (ROE) among peers: 7.81%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Zhejiang Hisun Pharmaceutical Co Ltd (600267) | CN¥8.76 Billion | 28.82% | 0.75x | $2.03 Billion |
| Shenzhen Neptunus Bioengineering Co Ltd (000078) | $205.69 Million | 15.10% | 2.12x | $1.05 Billion |
| Anhui Fengyuan Pharmaceutical Co Ltd (000153) | $765.24 Million | 1.30% | 0.72x | $438.59 Million |
| Shan Dong Dong-E E-Jiao Co Ltd (000423) | $1.12 Billion | 13.25% | 0.26x | $5.06 Billion |
| Livzon Pharmaceutical Group Inc (000513) | $1.01 Billion | 1.03% | 0.58x | $2.76 Billion |
| Wedge Industrial Co Ltd (000534) | $551.68 Million | 1.40% | 0.01x | $2.94 Billion |
| Yunnan Baiyao Group Co Ltd (000538) | $740.30 Million | 23.15% | 0.72x | $13.74 Billion |
| Hainan Haiyao Co Ltd (000566) | $317.39 Million | 7.74% | 0.74x | $958.72 Million |
| Tus Pharmaceutical Group Co Ltd (000590) | $271.26 Million | 1.07% | 1.01x | $386.52 Million |
| Northeast Pharmaceutical Group Co Ltd (000597) | $5.16 Billion | 6.95% | 1.96x | $1.04 Billion |
| Jilin Aodong Pharmaceutical Group Co Ltd (000623) | $25.04 Billion | 7.11% | 0.16x | $3.29 Billion |
About Zhejiang Hisun Pharmaceutical Co Ltd
Zhejiang Hisun Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of biological and generic drugs in China. The company provides active pharmaceutical ingredients and finished dosage form products. It offers products for anti-tumor, anti-infection, cardiovascular, endocrine, immunosuppression, antidepressant, liver care, and orthopaedics treatment; and weight loss… Read more